CN107625735A - A kind of pharmaceutical composition containing Atorvastatin calcium - Google Patents
A kind of pharmaceutical composition containing Atorvastatin calcium Download PDFInfo
- Publication number
- CN107625735A CN107625735A CN201610547155.6A CN201610547155A CN107625735A CN 107625735 A CN107625735 A CN 107625735A CN 201610547155 A CN201610547155 A CN 201610547155A CN 107625735 A CN107625735 A CN 107625735A
- Authority
- CN
- China
- Prior art keywords
- atorvastatin calcium
- pharmaceutical composition
- lactis anhydrous
- mesh sieves
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to pharmaceutical technology field, and in particular to a kind of pharmaceutical composition containing Atorvastatin calcium, described pharmaceutical composition contains Atorvastatin calcium, filler, disintegrant and lubricant, also containing Lactis Anhydrous and gelatin.The product stability of the invention of the present invention is good, and dissolution is complete, has more outstanding product quality；Operation is simple for the production of the present invention, is suitable for industrial production.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of pharmaceutical composition and its piece containing Atorvastatin calcium
The preparation method of agent.
Background technology
Atorvastatin calcium, chemical name：7- [2- (4- fluorophenyls) -3- phenyl -4- (anilino- formoxyl) -5- (2- third
Base) pyrroles -1- bases] -3,5- dihydroxy enanthic acid calcium；[R, (R ﹡, R ﹡)] -2- (4- fluorophenyls)-Β, Α-dihydroxy -5- (1- first
Base ethyl) -3- phenyl-[(anilino-)-hydroxyl] -1H- pyrroles -1- Calcium salt enanthates (2:1), it is a kind of 3- hydroxy-3-methyls penta
Two acyls-CoA-reductase (HMG-CoA reductase) inhibitor, for hypercholesterolemia and hyperlipidemia.
Atorvastatin calcium be it is a kind of to heat, moisture, the sensitive unstable material of light and low pH, and atomic molten in water,
Atorvastatin calcium is transformed into lactone form (US5686104 from carboxylic acid form under these conditions；Hurley, T.R. etc.,
Tetrahedron (1993), 49,1979-1984).The problems such as disintegration delay, dissolution is slow be present in atorvastatin agent,
Directly affect its clinical drug effect.
The content of the invention
It is an object of the invention to provide a kind of new pharmaceutical composition containing Atorvastatin calcium, said composition is made general
Logical tablet.
It is an object of the invention to provide a kind of new pharmaceutical composition containing Atorvastatin calcium, should cut down him containing atropic
The stability of the pharmaceutical composition of spit of fland calcium is good, and dissolution is complete.
It is another object of the present invention to provide a kind of preparation method of the pharmaceutical composition containing Atorvastatin calcium,
This method is adapted to industrial production.
Specifically, the invention provides：
A kind of pharmaceutical composition containing Atorvastatin calcium, contains：Atorvastatin calcium, disintegrant and lubricant, also
Contain Lactis Anhydrous and gelatin.
The described pharmaceutical composition containing Atorvastatin calcium is tablet.
The described pharmaceutical composition containing Atorvastatin calcium, the weight ratio of each component are：
Described disintegrant is selected from dried starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, crosslinked polyethylene pyrroles
One or more in alkanone, Ac-Di-Sol.
One or more of the described lubricant in superfine silica gel powder, talcum powder, magnesium stearate.
The described pharmaceutical composition containing Atorvastatin calcium prepares piece agent, and its preparation method comprises the following steps：
(1) after the Lactis Anhydrous of the Atorvastatin calcium of 10~40 parts by weight, 10~40 parts by weight is mixed, microwave is carried out
Vacuum drying,；
(2) Atorvastatin calcium obtained by step (1) is crushed with Lactis Anhydrous mixture, crosses 80~100 mesh sieves, it is standby
With；
(3) Lactis Anhydrous of surplus, 4~20 part by weight of disintegrant, 1~5 parts by weight lubricant are crossed 80~100 respectively
It is standby after mesh sieve；
(4) by the Lactis Anhydrous, disintegrant, lubricant of the surplus after sieving, the mixture obtained by step (2) pours into mixed
Mixed in conjunction machine；
(5) mixture of step (4) is crushed, crosses 80~100 mesh sieves；
(6) particle obtained by step (5) is added into gelatin to mix as adhesive, granulation, tabletting.
The present invention has the advantages that compared with prior art：
1st, product stability of the invention is good, and dissolution is complete.
2nd, operation is simple for production of the invention, is suitable for industrial production.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not the limit to the present invention
System, those skilled in the art according to the present invention basic thought, various modifications may be made or improve, but without departing from this
The basic thought of invention, within the scope of the present invention.
Test method
Dissolution rate takes atorvastatin, according to dissolution method (two annex X C second of Chinese Pharmacopoeia version in 2010
Method), using water 900ml as dissolution medium, rotating speed is 50 turns per minute, is operated in accordance with the law, during through 30 minutes, takes solution, is filtered, as
Need testing solution；Atorvastatin calcium reference substance (being approximately equivalent to Atorvastatin 10mg) separately is taken, it is accurately weighed, put 20ml measuring bottles
In, add 50% acetonitrile to make dissolving, shake up, precision measures 1ml, puts in 50ml measuring bottles, is diluted with water to scale, shake up, as right
According to product solution.Take above two solution, according to it is ultraviolet can-see AAS (two annex IV A of Chinese Pharmacopoeia version in 2010),
Determine absorbance respectively at 244nm wavelength, calculate the stripping quantity of every.
Relevant material takes product appropriate, adds 50% acetonitrile to be ultrasonically treated, and dissolves Atorvastatin calcium and quantifies dilution system
Solution into every 1ml containing about Atorvastatin 1mg, filtration, takes subsequent filtrate as need testing solution；Precision measures in right amount, uses
Solution in every 1ml containing about 1 μ g/ml is made as contrast solution in 50% dilution in acetonitrile.According to high performance liquid chromatography (Chinese Pharmacopoeia
Two D of annex V of version in 2010) experiment is filler with octyl silane group silica gel；With tetrahydrofuran-acetonitrile-ammonium acetate
Solution (takes ammonium acetate 3.9g, adds water 1000ml to make dissolving, be 5.0) (12 with glacial acetic acid regulation pH value:21:67) it is mobile phase A,
Tetrahydrofuran-acetonitrile-ammonium acetate solution (12:61:27) it is Mobile phase B, according to the form below carries out gradient elution, and Detection wavelength is
244nm；Precision measures need testing solution and each 20 μ l injections liquid chromatograph of contrast solution, records chromatogram.Need testing solution
If any impurity peaks, wherein impurity A (relative retention time 0.8), impurity B (relative retention time 0.9), impurity in chromatogram
C (relative retention time 1.2) peak area cannot be greater than 2.5 times (0.25%) of contrast solution main peak area, other single
The peak area of impurity cannot be greater than 2 times (0.2%) of contrast solution main peak area, each impurity peak area and cannot be greater than compareing
20 times (2.0%) of the main peak area of solution, it is any in need testing solution chromatogram to be less than 0.05 times of contrast solution main peak area
Peak can be neglected.
Assay shines high effective liquid chromatography for measuring (Chinese Pharmacopoeia two annex of version in 2010D) determine.
Chromatographic condition is filler with octyl silane group silica gel with system suitability；With tetrahydrofuran-acetonitrile-
Ammonium acetate solution (takes ammonium acetate 3.9g, adds water 1000ml to make dissolving, be 5.0) (12 with glacial acetic acid regulation pH value:21:67) it is stream
Dynamic phase；Detection wavelength is 244nm；Column temperature isFlow velocity is 1.5ml/min；Take respectively Atorvastatin calcium reference substance and Ah
Atorvastatin impurity B reference substance is appropriate, dissolved with 50% acetonitrile and dilute be made in every 1ml reference substance containing Atorvastatin calcium and
Each about 50 μ g of Atorvastatin impurity B reference substance mixed solution, takes 20 μ l to inject liquid chromatograph, records chromatogram, atropic
Cutting down the separating degree at statin peak and Atorvastatin impurity B peak should meet the requirements.
Determination method takes this product 20, accurately weighed, finely ground, and precision weighs appropriate (being approximately equivalent to Atorvastatin 10mg),
Put in 100ml measuring bottles, add 50% acetonitrile appropriate, supersound process makes dissolving, adds 50% dilution in acetonitrile to be shaken up, filtration, essence to scale
It is close to measure the μ l of subsequent filtrate 20 injection liquid chromatographs, record chromatogram；Separately Atorvastatin calcium reference substance is taken (to be approximately equivalent to atropic
Cut down statin 10mg), it is accurately weighed, put in 100ml measuring bottles, add 50% acetonitrile to dissolve and be diluted to scale, shake up, be measured in the same method.
By external standard method with calculated by peak area, produce.
Lactis Anhydrous is purchased from Kang Fu bioengineering Co., Ltd of Zhengjiang City.
Test example 1：Adhesive screens
Take respectively Atorvastatin calcium 30g (content 99.9%, it is total it is miscellaneous 0.09%), Lactis Anhydrous 70g, cross-linked carboxymethyl is fine
Plain sodium 8g, superfine silica gel powder 3g, adhesive 5g are tieed up, atorvastatin agent is prepared and by CN102309462A side by following prescriptions
Product made from method (dosage 3 of embodiment 3 is comparative example).
1 Formulation of table-adhesive screening
| Prescription | Adhesive |
| 1 | Polyvinylpyrrolidone |
| 2 | Carboxymethyl cellulose |
| 3 | Cellulose ether |
| 4 | Part pregelatinized corn starch |
| 5 | Gelatin |
Preparation method：
(1) after 30g Atorvastatin calcium, 30g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with milk-sugar mixture, crosses 80 mesh sieves, it is standby；
(3) after 40g Lactis Anhydrouses, 8g Ac-Di-Sols, 3g superfine silica gel powders being crossed into 80~100 mesh sieves respectively,
It is standby；
(4) by the 40g Lactis Anhydrouses after sieving, 8g Ac-Di-Sols, 3g superfine silica gel powders, step (2) gained
Mixture pour into mixer and mixed；
(5) mixture of step (4) is crushed, crosses 100 mesh sieves；
(6) particle obtained by step (5) is added into adhesive 5g to mix, granulation, tabletting.
It the results are shown in Table 2.
The dissolution test result of table 2
As seen from the above table, during from gelatin as adhesive, the accumulation dissolution rate of different time keeps stable, illustrates, and
Product quality more than 95% obtained by the present invention is stable, and result of extraction is good.
Test example 2：Influence factor is tested
The product of Example 3,5,6,8 and produced by CN102309462A methods (dosage 3 of embodiment 3 is comparative example) are obtained
Product carry out influence factor experiment, the results are shown in Table 3.
The influence factor test data of table 3
Conclusion：Road as seen from the above table, the product prepared by the inventive method, stability under high temperature and illumination better than pair
Ratio.
Test example 3：Accelerated test
The product of Example 3,5,6,8 and produced by CN102309462A methods (dosage 3 of embodiment 3 is comparative example) are obtained
Product carry out accelerated test, the results are shown in Table 4.
The accelerated test data of table 4
Packaging：Commercially available back, investigate condition：40 DEG C of temperature, humidity 75%
Conclusion：Road as seen from the above table, the product prepared by the inventive method, stability under high temperature and illumination better than pair
Ratio.
Preparation example
Embodiment 1
Prescription
Preparation method
(1) after 10g Atorvastatin calcium, 10g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with Lactis Anhydrous mixture, crosses 80 mesh sieves, it is standby；
(3) it is standby after remaining 40g Lactis Anhydrouses, 4g dried starch, 1.8g superfine silica gel powders being crossed into 80 mesh sieves respectively；
(4) Lactis Anhydrous, dried starch, superfine silica gel powder after step (3) is sieved, step (2)
The mixture of gained, which is poured into mixer, to be mixed；
(5) mixture of step (4) is crushed, crosses 80 mesh sieves；
(6) particle obtained by step (5) is added into gelatin to mix as adhesive, granulation, tabletting.
Embodiment 2
Prescription
Preparation method
(1) after 15g Atorvastatin calcium, 15g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with Lactis Anhydrous mixture, crosses 80 mesh sieves, it is standby；
(3) it is standby after 30g Lactis Anhydrouses, 8g sodium carboxymethyl starches, 2.8g talcum powder being crossed into 80 mesh sieves respectively；
(4) Lactis Anhydrous, sodium carboxymethyl starch, talcum powder after step (3) is sieved, the mixture obtained by step (2)
Pour into mixer and mixed；
(5) mixture of step (4) is crushed, crosses 80 mesh sieves；
(6) particle obtained by step (5) is added into gelatin to mix as adhesive, granulation, tabletting.
Embodiment 3
Prescription
Preparation method
(1) after 20g Atorvastatin calcium, 10g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with Lactis Anhydrous mixture, crosses 100 mesh sieves, it is standby；
(3) it is standby after 30g Lactis Anhydrouses, 12g low-substituted hydroxypropyl celluloses, 2.5g superfine silica gel powders being crossed into 100 mesh sieves respectively
With；
(4) by the Lactis Anhydrous of the surplus after sieving, low-substituted hydroxypropyl cellulose, micro mist silicon, obtained by step (2)
Mixture is poured into mixer and mixed；
(5) mixture of step (4) is crushed, crosses 100 mesh sieves；
(6) particle obtained by step (5) is added into gelatin to mix as adhesive, granulation, tabletting.
Embodiment 4
Prescription
Preparation method
(1) after 25g Atorvastatin calcium, 10g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with Lactis Anhydrous mixture, crosses 100 mesh sieves, it is standby；
(3) it is standby after 25g Lactis Anhydrouses, 15g PVPPs, 2.5g magnesium stearates being crossed into 80 mesh sieves respectively
With；
(4) by the Lactis Anhydrous after sieving, PVPP, magnesium stearate, the mixture obtained by step (2)
Pour into mixer and mixed；
(5) mixture of step (4) is crushed, crosses 100 mesh sieves；
(6) particle obtained by step (5) is added into gelatin to mix as adhesive, granulation, tabletting.
Embodiment 5
Prescription
Preparation method
(1) after 30g Atorvastatin calcium, 40g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with Lactis Anhydrous mixture, crosses 80 mesh sieves, it is standby；
(3) 40g Lactis Anhydrouses, 16g Ac-Di-Sols, 1.2g superfine silica gel powders, 0.5g magnesium stearates are distinguished
It is standby after crossing 80 mesh sieves；
(4) by the Lactis Anhydrous after sieving, Ac-Di-Sol, superfine silica gel powder, magnesium stearate, step (2) institute
The mixture obtained, which is poured into mixer, to be mixed；
(5) mixture of step (4) is crushed, crosses 100 mesh sieves；
(6) particle obtained by step (5) is added into gelatin to mix as adhesive, granulation, tabletting.
Embodiment 6
Prescription
Preparation method
(1) after 35g Atorvastatin calcium, 25g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with milk-sugar mixture, crosses 100 mesh sieves, it is standby；
(3) 60g Lactis Anhydrouses, 6g dried starch, 4g sodium carboxymethyl starches, 0.8g talcum powder, 0.5g magnesium stearates are distinguished
It is standby after crossing 100 mesh sieves；
(4) by the Lactis Anhydrous after sieving, dried starch, sodium carboxymethyl starch, talcum powder, magnesium stearate, step (2) gained
Mixture pour into mixer and mixed；
(5) mixture of step (4) is crushed, crosses 100 mesh sieves；
(6) particle obtained by step (5) is added into 5.0g gelatin to mix as adhesive, granulation, tabletting.
Embodiment 7
Prescription
Preparation method
(1) after 40g Atorvastatin calcium, 30g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with milk-sugar mixture, crosses 80 mesh sieves, it is standby；
(3) by 30g Lactis Anhydrouses, 7g low-substituted hydroxypropyl celluloses, 5g Ac-Di-Sols, 4g superfine silica gel powders
It is standby after crossing 80 mesh sieves respectively；
(4) by the Lactis Anhydrous of the surplus after sieving, low-substituted hydroxypropyl cellulose, Ac-Di-Sol,
Superfine silica gel powder, the mixture obtained by step (2), which is poured into mixer, to be mixed；
(5) mixture of step (4) is crushed, crosses 80 mesh sieves；
(6) particle obtained by step (5) is added into 4.2g gelatin to mix as adhesive, granulation, tabletting.
Embodiment 8
Prescription
Preparation method
(1) after 10g Atorvastatin calcium, 10g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with milk-sugar mixture, crosses 100 mesh sieves, it is standby；
(3) by 25g Lactis Anhydrouses, 5g sodium carboxymethyl starches, 9.2g low-substituted hydroxypropyl celluloses, 1.5g superfine silica gel powders point
It is standby after not crossing 100 mesh sieves；
(4) by the Lactis Anhydrous after sieving, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, superfine silica gel powder, step
(2) mixture obtained by, which is poured into mixer, to be mixed；
(5) mixture of step (4) is crushed, crosses 100 mesh sieves；
(6) particle obtained by step (5) is added into 2.3g gelatin to mix as adhesive, granulation, tabletting.
Embodiment 9
Prescription
Preparation method
(1) after 20g Atorvastatin calcium, 20g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with Lactis Anhydrous mixture, crosses 100 mesh sieves, it is standby；
(3) by 35g Lactis Anhydrouses, 6g PVPPs, 3g Ac-Di-Sols, 3g talcum powder point
It is standby after not crossing 80~100 mesh sieves；
(4) by the Lactis Anhydrous after sieving, PVPP, Ac-Di-Sol, talcum powder, step
Suddenly the mixture obtained by (2), which is poured into mixer, is mixed；
(5) mixture of step (4) is crushed, crosses 80 mesh sieves；
(6) particle obtained by step (5) is added into 3.2g gelatin to mix as adhesive, granulation, tabletting.
Embodiment 10
Prescription
Preparation method
(1) after 40g Atorvastatin calcium, 30g Lactis Anhydrous are mixed, micro-wave vacuum is carried out；
(2) Atorvastatin calcium obtained by step (1) is crushed with Lactis Anhydrous mixture, crosses 80 mesh sieves, it is standby；
(3) it is 40g Lactis Anhydrouses, 10g mannitol, 9g sodium carboxymethyl starches, 10g low-substituted hydroxypropyl celluloses, 5g is micro-
It is standby after powder silica gel crosses 80 mesh sieves respectively；
(4) by the Lactis Anhydrous of the surplus after sieving, mannitol, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose,
Superfine silica gel powder, the mixture obtained by step (2), which is poured into mixer, to be mixed；
(5) mixture of step (4) is crushed, crosses 100 mesh sieves；
(6) particle obtained by step (5) is added into 4.1g gelatin to mix as adhesive, granulation, tabletting.
Claims (6)
1. a kind of pharmaceutical composition containing Atorvastatin calcium, pharmaceutical composition contain Atorvastatin calcium, disintegrant and profit
Lubrication prescription, it is characterised in that pharmaceutical composition contains Lactis Anhydrous and gelatin.
2. the pharmaceutical composition according to claim 1 containing Atorvastatin calcium, it is characterised in that pharmaceutical composition system
Standby piece agent.
3. the pharmaceutical composition according to claim 1 containing Atorvastatin calcium, it is characterised in that the weight of each component
Than for：
4. the pharmaceutical composition according to claim 1 containing Atorvastatin calcium, it is characterised in that described disintegrant
Selected from dried starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, PVPP, cross-linked carboxymethyl fiber
One or more in plain sodium.
5. the pharmaceutical composition according to claim 1 containing Atorvastatin calcium, it is characterised in that described lubricant
One or more in superfine silica gel powder, talcum powder, magnesium stearate.
6. the preparation method of the pharmaceutical composition according to claim 1 containing Atorvastatin calcium, comprises the following steps：
(1) after the Lactis Anhydrous of the Atorvastatin calcium of 10~40 parts by weight, 10~40 parts by weight is mixed, microwave vacuum is carried out
Dry,；
(2) Atorvastatin calcium obtained by step (1) is crushed with Lactis Anhydrous mixture, crosses 80~100 mesh sieves, it is standby；
(3) Lactis Anhydrous of surplus, 4~20 part by weight of disintegrant, 1~5 parts by weight lubricant are crossed into 80~100 mesh sieves respectively
Afterwards, it is standby；
(4) by the Lactis Anhydrous, disintegrant, lubricant of the surplus after sieving, the mixture obtained by step (2) pours into mixer
In mixed；
(5) mixture of step (4) is crushed, crosses 80~100 mesh sieves；
(6) particle obtained by step (5) is added into gelatin as adhesive, granulation, tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610547155.6A CN107625735A (en) | 2016-07-13 | 2016-07-13 | A kind of pharmaceutical composition containing Atorvastatin calcium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610547155.6A CN107625735A (en) | 2016-07-13 | 2016-07-13 | A kind of pharmaceutical composition containing Atorvastatin calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107625735A true CN107625735A (en) | 2018-01-26 |
Family
ID=61112093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610547155.6A Pending CN107625735A (en) | 2016-07-13 | 2016-07-13 | A kind of pharmaceutical composition containing Atorvastatin calcium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107625735A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101791297A (en) * | 2010-02-10 | 2010-08-04 | 中国药科大学 | Atorvastatin calcium oral disintegrating tablet and preparation method thereof |
| CN102139115A (en) * | 2011-03-30 | 2011-08-03 | 天津红日药业股份有限公司 | Preparation method for atorvastatin cyclodextrin inclusion compound and oral solid preparation thereof |
| CN102309462A (en) * | 2011-07-16 | 2012-01-11 | 南京正宽医药科技有限公司 | Atorvastatin calcium tablet |
-
2016
- 2016-07-13 CN CN201610547155.6A patent/CN107625735A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101791297A (en) * | 2010-02-10 | 2010-08-04 | 中国药科大学 | Atorvastatin calcium oral disintegrating tablet and preparation method thereof |
| CN102139115A (en) * | 2011-03-30 | 2011-08-03 | 天津红日药业股份有限公司 | Preparation method for atorvastatin cyclodextrin inclusion compound and oral solid preparation thereof |
| CN102309462A (en) * | 2011-07-16 | 2012-01-11 | 南京正宽医药科技有限公司 | Atorvastatin calcium tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103933000B (en) | Azilsartan tablet and preparation method thereof | |
| CN103610650A (en) | Isosorbide mononitrate sustained-release pallets, preparation prepared from same and preparation method for isosorbide mononitrate sustained-release pallets | |
| CN104840427B (en) | A kind of pharmaceutical composition containing Menglusitena | |
| CN108553433A (en) | A kind of Azilsartan piece and preparation method thereof | |
| Todaro et al. | Development and characterization of ibuprofen co-crystals granules prepared via fluidized bed granulation in a one-step process–a design of experiment approach | |
| CN106074422A (en) | A kind of succinum love song Ge Lieting oral solid formulation and preparation method thereof | |
| CN107625735A (en) | A kind of pharmaceutical composition containing Atorvastatin calcium | |
| CN104840460B (en) | A kind of pharmaceutical composition containing Valsartan and Amlodipine | |
| CN106053663A (en) | Method for determining releasing rate of enteric sustained-release tablet | |
| CN109953966A (en) | A kind of pharmaceutical composition and preparation method thereof containing Rui Boxini | |
| CN103494818B (en) | Nicotinic acid and simvastatin sustained release tablets and method for manufacturing same | |
| CN104688695B (en) | A kind of pharmaceutical composition containing voriconazole | |
| CN103989680B (en) | A kind of pharmaceutical composition containing Pitavastatin Calcium | |
| CN104688696B (en) | A kind of pharmaceutical composition containing candesartan Cilexetil | |
| CN103385863B (en) | Sodium azulene sulfonate sustained-release preparation | |
| CN106880597A (en) | A kind of everolimus piece | |
| CN104688694B (en) | A kind of pharmaceutical composition containing bisulfate clopidogrel | |
| CN115887393B (en) | Olmesartan medoxomil tablet and preparation method thereof | |
| CN104483411A (en) | Detection method for Forsythia suspensa and product containing Forsythia suspensa | |
| CN105581989B (en) | A kind of pharmaceutical composition containing Fenofibric Acid | |
| CN115844847B (en) | Itopride hydrochloride preparation and preparation method thereof | |
| CN104666257B (en) | A kind of pharmaceutical composition containing terbinafine HCl | |
| CN115177594B (en) | Acetinib pharmaceutical preparation and preparation method thereof | |
| CN113133977B (en) | Afatinib maleate tablet and preparation method thereof | |
| CN109953965A (en) | A kind of pharmaceutical composition containing tartaric acid Mo Fanselin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180126 |